Bristol Myers Squibb Company (NYSE:BMY) is considered one of the most undervalued large cap stocks to invest in now. Piper Sandler raised the price target to $66 from $62, stating that the stock remains undervalued despite upcoming challenges. Citi analyst Geoff Meacham also raised the price target to $60, suggesting a favorable setup for growth in 2026.

Leerink analyst David Risinger raised the price target for Bristol Myers to $60 from $54 with an Outperform rating. The firm sees significant upside potential driven by a robust pipeline. Bristol Myers expects 12 data readouts from eight assets in 2026, indicating promising growth opportunities in the coming year.

Bristol Myers Squibb Company engages in the discovery, development, and distribution of biopharmaceutical products globally. The company operates in various therapeutic areas, including oncology, hematology, and neuroscience, among others. Its diverse product portfolio caters to a wide range of medical needs and markets.

Although Bristol Myers offers investment potential, some AI stocks may have greater upside and lower risk. Investors seeking undervalued AI stocks may benefit from exploring other opportunities. Consider exploring a free report on the best short-term AI stock for potential investment opportunities in the current market.

Read more at Yahoo Finance: Piper Sandler Raises Bristol Myers (BMY) PT to $66 Citing Pipeline Visibility